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ABSTRACT
Irritable bowel syndrome (IBS) is a common and
well-accepted diagnosis but often imprecisely
applied to patients in usual clinical practice.
Diagnosis is entirely based on symptom criteria
that tend to include broad strata of abdominal
complainers. Established criteria for diagnosis are
strictly followed incontrolled clinical trials fornew
therapeutic agents, but physicians are more lax in
the clinic. Predictably, in light of the above
ambiguities, many pathogenetic mechanisms
and pathophysiological disturbances appear to be
involved in IBS, but so far no mechanism-based
subgroupings to guide specific therapy have been
soundly established. Thus, diverse therapeutic
approaches coexist and are discretionally
prescribed by attending clinicians on the basis of
majormanifestations (i.e., diarrhea-predominance
or constipation-predominance), more or less
apparent psychological disturbances, and patient
preferences (pharmacological versus dietary or
microbiological approaches). In this review, we
have attempted to update scientific knowledge
about the more relevant disease mechanisms
involved and relate this more fundamental basis
to the various treatment options available today.
Keywords: Gastroenterology; Irritable bowel
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GENERAL CONSIDERATIONS
In Western countries, irritable bowel syndrome
(IBS) is a common medical condition with
prevalence figures that hover around 10–15%
[1]. Other countries around the world also
report high prevalence figures, albeit more
variable. IBS also constitutes a substantial
fraction of specialist consultations that, in the
USA, has been estimated to be close to 20% [2].
IBS impacts considerably on a patient’s daily
living and quality of life while increasing
healthcare resource use and expenditure.
Consequently, IBS results in a substantial
financial and economic burden including costs
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for consultations, diagnostic tests, medications,
and preventive measures together with
substantial productivity losses.
IBS is a term that currently enjoys favor with
medical professionals and it is also increasingly
recognized as a valid diagnosis by patients.
However, the definition and especially the
scope of IBS as a medical condition remain
somewhat imprecise because its diagnosis is
entirely symptom-based and there are no
biomarkers or diagnostic technologies
available for precise characterization [3, 4].
Since 1992, there have been four major
consecutive attempts at defining IBS by
consensus during medical expert meetings in
Rome, the last being held in 2015. The
successively refined definition of IBS that has
emerged from these Rome meetings has been
helpful in popularizing the term IBS and
providing concrete symptom criteria. In turn,
these established criteria have enabled
regulatory agencies to standardize the
requirements for the performance of
randomized control trials, subsequently
conducted by pharma industries striving to
obtain approval for new drugs intended for
treatment of IBS. From the above perspective,
the Rome process has yielded generally
accepted outcomes and proven value.
However, problems remain with the
exclusively symptom-based definition of IBS
that risks mixing pathophysiologies and
possibly even etiologies within trial study
groups. Furthermore, concerns have been
expressed about the difficulties that would be
encountered in the future to disentangle the
current terminology should new methods be
developed to establish the diagnosis beyond
exclusive symptom criteria. Furthermore, as
pointed out by Quigley and Shanahan [5], an
exclusively symptom-based definition of a
medical condition such as IBS and other
functional syndromes may unintentionally
create an illusion of understanding and equate
complaints with ‘‘disease’’. Such risk is already
noticeable in clinical practice as physicians
often include cases of unexplained abdominal
pain into the IBS diagnosis without specifically
checking whether all these patients really meet
published Rome criteria [6].
Another important aspect of IBS diagnosis,
which is highly relevant to therapeutic
strategies, is the fact that patients with IBS
often manifest associated extraintestinal
symptoms and comorbid conditions. Among
the most common are fatigue, musculoskeletal
pain, headaches, sleep disturbance, urinary
symptoms, and comorbidities such as
fibromyalgia, chronic fatigue syndrome,
intestinal cystitis, sicca syndrome,
post-traumatic stress disorder,
temporomandibular joint disorder, and chronic
pelvic pain [7]. These associated symptoms and
comorbidities raise the following question: are
we dealing with a gastroenterological or a
systemic medical problem? Indeed, as reasoned
by Ross [8], there may be an element of ‘‘meme’’
contagion fuelling the astonishingly high
prevalence of IBS symptoms in many Western
societies. The IBS ‘‘meme’’ perspective implies
that the IBS label itself becomes a useful and
compelling idea capable of inducing
psychosomatic illness in vulnerable ‘‘hosts’’.
Furthermore, symptoms themselves may be
promoted and amplified by medical
professionals eager to establish a diagnosis.
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
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APPROACHING IBS THERAPY
FROM A PATHOPHYSIOLOGICAL
PERSPECTIVE
Any therapeutic approach to IBS should
contemplate the aspects outlined in Table 1,
including epidemiological data applicable to an
individual patient, the specific symptomatology
and severity of illness, the associated
manifestations, and comorbidities that may be
present, and the personality traits and
psychosomatic aspects, which cannot be
ignored. These various features may provide
useful hints about the pathogenetic
mechanisms operating in a given patient,
helping us direct the various potential
therapeutic measures in the most efficient
way. Let us consider next the most relevant
aspects of such a discriminating approach.
Immunological Gut Dysregulation
There is mounting evidence of altered gut
mucosal immune activity [9–11] including the
presence of mucosal immune cell infiltrates
[12], modified mucosal lymphocyte
phenotypes [13], mast cell proliferation in
proximity to nerve endings [14], and increased
apical junction complex permeability [15].
Furthermore, elevated levels of circulating
proinflammatory cytokines have been reported
[16]. There is also indication of microbial
induced mucosal immune activity based on
observations such as increased blood antibodies
against flagellin and increased antimicrobial
peptides such as B2 defensins. In certain
models there is evidence that probiotics (i.e.,
Bifidobacterium infantis, Faecalibacterium
prausnitzii) may diminish proinflammatory
Table 1 Known IBS pathophysiologic disturbances and suitable as therapeutic targets
Disturbances Targets
Immunological gut dysregulation Mucosal inﬂammation
Neuroimmune interactions
Altered microbial gut ecology SIBO
Excess bowel fermentation (carbohydrates, protein)
Short chain fatty acid production
Diet composition and tolerance Lactose, fructose, and gluten intolerance
FODMAP’s symptom induction
Prebiotic/symbiotic action
Food allergens
Brain–gut axis dysfunction Visceral hypersensitivity
Extraintestinal manifestations
Stress-induced CNS, ENS, HPA axis dysfunctions
Associated anxiety/depression
Bile acid malabsorption
Increased bile acid synthesis
Excess colonic bile acids
CNS central nervous system, ENS enteric nervous system, HPA hypothalamic–pituitary–adrenal, SIBO small intestine
bacterial overgrowth, FODMAP fermentable oligo-, di-, mono-saccharides and polyols
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cytokine activity (NF-jB and IL-8) providing
some mechanistic support for the therapeutic
use of probiotics in IBS.
Microbial Gut Ecology
Post-infectious IBS is a special form where
mucosal inflammation and abnormal gut–host
microbial interactions probably play a
particularly significant role [17].
Epidemiological data indicates that
post-infectious IBS may affect from 3% to 30%
of individuals developing infectious
gastroenteritis [18]. Predisposing factors
include female sex, younger age, prior
antibiotics, and concomitant depression.
Interestingly, psychological comorbidity
increases the risk of developing IBS via
enhanced susceptibility to develop infectious
gastroenteritis [19]. In post-infectious IBS,
mucosal immune activation and immune cell
proliferation may enhance peripheral sensory
signaling [20] and contribute to visceral
hypersensitivity which is considered a pivotal
symptom mechanism in IBS.
Microbiota alterations may also contribute
to the pathogenesis of IBS, but evidence so far is
spotty and sometimes contradictory. A
potential IBS disease mechanism involving
microbiota alterations is microbial
proliferation outside the main bacterial
reservoir, which is the so-called small intestine
bacterial overgrowth (SIBO) hypothesis. This
potential mechanism was initially proposed by
Pimentel et al. [21] and others about 20 years
ago. The concept of SIBO chiefly emanated from
reports of frequently positive lactulose H2
breath tests in patients with IBS. However,
other studies could find no difference between
diarrhea-predominant IBS (IBS-D),
constipation-predominant IBS (IBS-C), and
controls [22, 23], and data from culture of
jejunal aspirates proved inconclusive. It was
further argued that jejunal aspirates were not
representative of the distal small bowel luminal
environment where bacterial overgrowth might
be more significant and also that the
composition of the small bowel microbiota
differed between IBS and healthy controls. In
any case, the hypothesis that SIBO was a
relevant symptom mechanism in IBS was
underscored by the plausibility of a number of
putative mechanisms: small bowel
deconjugation of bile acids with liberation of
diarrheagenic moieties, generation of short
chain fatty acids and gases with increased 5HT
release and stimulation of ileal contractions,
endotoxin-induced hyperalgesia, and
production of a mucosal low grade
inflammatory state with increased visceral
hypersensitivity [24]. Indeed, some data
suggest correlation between fecal short chain
fatty acid content and IBS symptoms. Protein
fermentation in the small bowel could also lead
to increased production of hydrogen sulfides
that may alter epithelial metabolism and induce
visceral hypersensitivity. On the other hand,
the potential relevance of SIBO was
substantially weakened by the studies of Yu
et al. [25] that combined orocecal scintigraphic
measurements of transit with the conventional
lactulose H2 breath test. These investigators
evaluated 40 patients with IBS whose breath
tests were positive (applying conventional
criteria) and showed that 88% of these
patients had at least 5% of the radioactive
tracer in the cecum at the time of the H2
breath ascent. Thus, although this comparative
study does not exclude the possibility of SIBO, it
shows that breath test positivity is not a reliable
criterion since rapid transit of marker from
mouth to colon probably explains the
fallaciously high proportion of patients with
IBS so diagnosed.
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Alternative explanations to SIBO may
account for the symptomatic responses to
antibiotic treatment in IBS observed in some
studies. Such alternative explanations involve
alterations in fecal microbiota composition
that have been observed in patients with IBS.
These include qualitative and quantitative
changes in some bacterial families [26].
Interestingly, certain human microbiota
species appear to influence specific and
relevant gut functions. For instance,
F. prausnitzii may operate as a modulator of
colonic hypersensitivity [27] and Lactobacillus
reuteri as a regulator of colonic transit [28].
Unfortunately, progress in this area is
hampered by the absence of good biomarkers
of healthy microbiota to predict disease or to
help us monitor responses to agents acting of
human gut microbiota. Future research may
help clarify such aspects.
Diet Composition and Tolerance
Lactose intolerance relates to lactase
nonpersistence which may affect up to 65% of
the adult population [29]. True lactose
intolerance may induce IBS-like symptoms but
only with relatively high lactose loads ([20 g)
that are easily avoidable by forewarned patients.
On the other hand, psychological factors have a
major influence on the symptomatic responses
to lactose intake [30].
Fructose is a monosaccharide, abundantly
present in many processed foods. The human
small bowel has a relatively limited absorptive
capacity that particularly affects free fructose
which is the fraction in excess of the glucose
that facilitates fructose absorption [31]. Thus,
high fructose loads may induce symptoms even
in healthy individuals. Fructans and
galactooligosaccharides are poorly absorbed
short chain carbohydrates that may reach the
colon intact, increasing colonic production of
gas via fermentation. Polyols comprising
sorbitol, mannitol, and xylitol are also
naturally present in many fruits and
vegetables as well as added as artificial
sweeteners to industrial food products and
pharmaceuticals. They tend to induce bowel
discharges because of their stimulant effect on
intestinal motility [32]. The aforementioned
short chain fermentable carbohydrates are
collectively termed FODMAPs, and there is
direct evidence by magnetic resonance
imaging technology that among FODMAPs
there are some, like fructose, that may induce
symptoms via increased small bowel water
content whereas others, like fructans, increase
colonic gas production [33].
Heightened awareness of the role of gluten
sensitivity in the pathogenesis of celiac disease
has quickly evolved into the concept of ‘‘gluten
intolerance’’ portrayed as an IBS-like condition
clinically manageable by dietary gluten
restriction. This ‘‘gluten-free healthy diet’’
concept has rapidly spread to the fashion and
media community and from them to the
general population where it has acquired
many adepts. The marketing of gluten-free
food products has rapidly expanded in suit.
Uncertainties as to the pathogenesis of the
phenomenon and the actual therapeutic value
of gluten avoidance (total or partial) in these
individuals are still the subject of controversy.
Prebiotics are food products that favor
proliferation of bifidobacteria and other
species potentially associated with
anti-inflammatory effects (oligofructose,
inulin, galactooligosaccharides, lactulose,
breast milk oligosaccharides, and others).
Prebiotics do not seem particularly effective in
IBS possibly on account of fermentation
products that may, in themselves, stimulate
symptoms. The so-called synbiotics that aim to
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simultaneously produce synergic pro- and
prebiotic effects also have not encountered
much therapeutic success in IBS.
Specific components of the normal diet have
long been suspected to induce gastrointestinal
symptoms in susceptible individuals. In fact,
patients themselves often insist that they may
experience symptomatic responses to concrete
foods. This general concept of food intolerance
being the origin of IBS-like symptoms is
appealing but unfortunately there is little
evidence that it plays a clinically significant
role. There are a number of commercially
available tests that purportedly may be
employed to identify food intolerances but
without strict validation. Such tests include
allergen-specific IgG against several foods,
sublingual or intradermal provocation tests,
electrodermal tests, cytotoxic assays, or others.
None of these tests, although fairly popular
among concerned patients, is reliable enough to
be used as a basis for a dietary therapeutic
strategy. On the contrary, diet over-restrictions
may lead to nutritional inadequacies or social
complexities.
A recently developed test based on direct
observation of mucosal reactivity to specific
food antigens by endoscopic confocal laser
endomicroscopy is encouraging by its
simplicity and apparent objectivity [34], but
more studies are required to ascertain the
practical value of this enticing approach.
Relevance of the Brain–Gut Axis
Bidirectional communication between brain
and gut is essential for the regulation of
normal gut function and it seems critical to
the development of functional conditions such
as IBS [35].
Pain arising from the gut in functional
disorders is not simply a matter of stimulated
pain afferents by abnormal mechanical or
chemical stimuli. Amplified afferent signals
(by inflammation, sensitization, and other
local factors) result in disturbed pain signaling
[36]. Moreover, impaired descending pain
modulation further amplifies signals at the
central circuits for pain reception and
modulation. There is also a link between
emotion and cognitive pain modulation
implying that stress and anxiety have a major
influence on the perception of visceral signals.
The main central structures involved are the
amygdala, the hypothalamus, and the
periaqueductal gray. The main
information/control pathways for brain–gut
interaction involve both the autonomic
nervous system and the
hypothalamus–pituitary–adrenal (HPA) axis.
Autonomic nervous system disturbances may
influence gut reflex activity, perception, and
extraintestinal manifestations, common in IBS
and other functional gut disorders. Moreover,
anxiety/depression appears to facilitate gut
inflammation [37] closing the
neuroinflammatory brain–gut–brain loop.
Stress is increasingly recognized as an
important epidemiological and
pathophysiological player in IBS and other
functional disorders. Both early stressful events
and current chronic stress are important. Thus,
early adverse life events may produce
permanent epigenetic changes in both the
central and enteric nervous systems and also
sensitize the HPA axis [38]. Abuse may impact
upon central mechanisms of pain modulation,
affect, and attention. For instance, we know
that hippocampal suppressed neurogenesis
induced by stress reduces detection of novel
experiences and predisposes to depression [39].
Conversely, brain-derived neurotrophic factor
(BDNF) and Bcl-2 promote precursor
differentiation resulting in mood
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improvement and pain attenuation. In this
context, the HPA system does play a
significant role. Brain structures such as the
amygdala act as a link between emotional
arousal and corticotropin-releasing factor
(CFR)-dependent activation of the HPA. In
rodents, for instance, increased CRF and
urocortin I induce anxiety-like behavior and
increase gut sensitivity and motility. In
humans, experimental administration of
corticotropin-releasing hormone appears to
reproduce intestinal effects of experimental
stress [40].
The information compiled above leads to the
conclusion than abdominal pain, a key feature
of IBS, results from a combination of disturbed
peripheral pain signaling and disturbed
emotional and cognitive pain modulation. As
Drossman [41] has pointed out, functional
disorders are placed within the range that
spans from illness (personal experience of a
medical condition) to disease (abnormalities in
structure and function of organs and tissues). In
a given patient symptom, criteria are
insufficient to establish the precise location
within the spectrum; however, when the
physician carefully takes into consideration
the whole clinical picture, the relative weight
of central and peripheral mechanisms may be
ascertained and help in choosing well among
available therapeutic options.
Disturbed Bile Acid Homeostasis
Chronic diarrhea may be induced by excess bile
acids in the colon that stimulate motility and
mucus production. Bile acid malabsorption may
be observed after ileal resection,
cholecystectomy, and there is also an
idiopathic form induced by bile acid
overproduction in the liver [42]. Bile acid
malabsorption has been observed in some
patients with IBS-D and postulated as a
pathogenetic mechanism for their condition
[43–45].
CURRENT TREATMENT
APPROACHES FOR IBS
Taking into consideration the various potential
mechanisms involved in the pathogenesis of IBS
that we have succinctly reviewed above, one
may schematically classify treatment options as
shown below and summarized in Table 2:
• Treatments based on diet modifications.
• Treatments directed towards normalization
of microbiome ecology.
• Treatments directed against mucosal
inflammation.
• Treatments aiming to normalize intestinal
motility.
• Treatments directed to correct disturbances
along the brain–gut axis and its regulatory
pathways.
• Treatment of colonic bile acid overload.
Diet Modifications
Diet manipulations are a potential therapeutic
measure that has been quickly and broadly
assumed by the general consumer market
without complete understanding of the
mechanism of action, criteria for selection of
appropriate candidates for dietary adjustments,
or guidance for long-term use. Initially, diet
recommendations were based on conventional
‘‘common sense’’ and tradition: regular meals,
well chewed, avoidance of alcohol, coffee,
spices, and greasy foods, etc. Other approaches
to dietary control of IBS symptomatology merit
consideration. A particularly challenging aspect
is the potential effect of bioactive chemicals
present in food such as caffeine, histamine,
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salicylates, and monosodium glutamate to cite a
few. Unfortunately it is difficult to design diets
that exclude food additives and food chemicals
because these industrial molecules are
widespread, and highly restricted diets could
potentially lead to nutritional inadequacies.
A preeminent antifermentation diet is the
so-called low FODMAP diet. The key principle
behind this diet is to reduce the intake of poorly
absorbed short chain carbohydrates and
fermentable vegetables. These food products
generate osmotically active substances,
generate short chain fatty acids, and increase
gas production all of which are poorly tolerated
by IBS patients [46–48]. Clinical supporting
evidence includes a recent randomized
controlled trial by Halmos et al. [49] showing
that placement of IBS patients on a
FODMAP-restricted diet for 3 weeks
significantly improves their symptoms and
well-being. Interestingly, adding gluten
restriction to patients with non-celiac gluten
intolerance does not further improve the
response to low FODMAP.
A strict low FODMAP diet is not easy to
sustain in the long term, which may account for
partial or short-term responses outside
controlled trials [50], but it is not a
nutrient-deficient diet and fulfills current
nutritional standards. However, a low
FODMAP diet affects the gut microbiota and
we ignore the potential long-term consequences
Table 2 Current treatment approaches in IBS
Mechanism-oriented aim Treatment modalities and drugs
Diet modiﬁcations Withdrawal of excitatory/irritant substances
Low FODMAP diet
Speciﬁc dietary avoidances: lactose, gluten,
others
Restoring microbiome ecology Modifying intraluminal substrates
Probiotics
Reducing mucosal inﬂammation Mast cell, eosinophil stabilizers
Anti-inﬂammatory drugs (potential)
Drugs acting upon motility/secretory mechanisms Antispasmodics, antidiarrheals
Linaclotide, lubiprostone
Gut antibiotics (clearing SIBO; microbiome modulation) Rifaximin, others
Neurogastroenterological disturbances (central, intermediate pathways,
enteric)
Psychological approaches
Antidepressants: SSRIs, SNRIs, H1 drugs,
tricyclics
Intestinal ﬂuid/motor dynamics Alosetron, ondansetron, ramosetron
Loperamide, Eluxadoline
Excess colonic bile acids Cholestyramine, colestipol, colesevelam
SIBO small intestine bacterial overgrowth, SNRI serotonin–norepinephrine reuptake inhibitor, SSRI selective serotonin
reuptake inhibitor
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of this induced change. Thus, exclusion diets as
a general principle should be used for as short a
time as possible [51]. Furthermore, others have
pointed out that time-honored dietary
recommendations for patients with chronic
digestive symptoms such as small meals,
reduced caffeine, reduced fat, and excess fiber,
plus avoidance of well-known gas-producing
foodstuffs may achieve similar results as a low
FODMAP diet and are easier for patients to grasp
and adhere to [52].
Restoring Microbiome Ecology
There are a substantial number of appealing
candidates to influence microbiome ecology for
therapeutic intervention in IBS. However, solid
proof of significant beneficial action remains
elusive for many of the proposed agents. The
chief categories are (a) probiotics, i.e., optimal
natural bacterial strains (perhaps genetically
modified strains in the future); (b) diet
manipulations to eliminate or enrich
substrates metabolized by bacteria;
(c) nonabsorbable antibiotics to actively
modify the microbiota ecobalance; and
(d) fecal bacteriotherapy that aims at
transplanting a foreign colonic flora to
re-establish the physiological ecobalance.
Probiotics have become a highly popular
medical and paramedical resource for the
treatment of IBS and many other functional
gastrointestinal disorders. The easy accessibility,
fashionability, and perceived safety of
probiotics have led to widespread use without
much medical modulatory influence or
regulatory control. Currently, it is not possible
to ascertain whether probiotics, as a class, are
indeed useful in the management of IBS. As
Shanahan and Quigley [24] have recently
pointed out, there are many soft claims
plaguing probiotics: labels without verification
by controlled human studies, substantial gaps
between research findings and marketplace
claims, unmet label assertions on numbers and
type of viable microbes in commercial probiotic
products, and also about quantities of bacteria
required to obtain health benefits. Finally, in
some instances, shelf-life specifications are not
displayed. The current situation reflects in real
life the challenges of objectively and ethically
translating science into consumer value.
Scientists make enticing laboratory
observations that sometimes are channeled too
quickly by the media without sufficient
assessment by regulatory bodies and pushed
by eager industries into market distribution
without clear-cut evidence of efficacy. Some
probiotics have been evaluated by well-designed
and robust trials and appear to be effective on
certain symptoms under some conditions
[53–56], but other probiotic trials have been
unsuccessful [57–59].
Many probiotics are commercially available
and in fact often tried by patients with IBS with
or without professional advice. However, the
drawbacks pointed out above remain an
obstacle to well-founded medical prescription.
Yet, some aspects of probiotic therapy are
particularly appealing, such as the concept of
a microbiota–brain–gut axis [60, 61]. Indeed,
under certain conditions probiotic bacteria may
modulate behavior and brain biochemistry via
the vagus nerve [62] and other neural and
endocrine pathways. Moreover, prior data
suggest that anxiety/depression facilitate gut
inflammation [63] and, conversely,
Bifidobacterium longum may reduce brain
emotional reactivity in IBS [64]. Thus,
probiotic-induced changes in the gut
microbiota appear to modify gut neuromotor
functions.
These encouraging laboratory data would
support a role for probiotics in the treatment
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of IBS, but outcomes of clinical studies remain
equivocal and sometimes contradictory. As
pointed out earlier, the lack of good
biomarkers of healthy microbiota to predict
disease has slowed down progress in search for
appropriate probiotic therapy. Future progress
in this field is likely to produce useful advances.
Acting on Gut Mucosal Inflammation
Intestinal inflammation, be it post-infectious,
allergic, or idiopathic, is a recognizable feature,
especially in IBS-D but also in other IBS
subgroups. Some years ago, it was observed
that chronic users of steroids were at a reduced
risk for developing IBS [65]. Disappointingly,
however, additional studies showed that
treatment of patients with post-infectious IBS
with prednisolone was not clinically efficacious
[66], and two recent trials of mesalazine
treatment in IBS yielded negative outcomes
[67, 68]. On the other hand, a small trial with
the mast cell stabilizer ketotifen has produced
encouraging results [69]. The negative results of
the mesalazine trials have somewhat dampened
the enthusiasm for the concept of
anti-inflammatory therapy in IBS; however, as
To¨rnblom and Simren [70] have recently
pointed out, given the current obstacles to
select potentially responsive IBS subgroups and
lack of consensus on primary endpoints to
measure, it may be premature to give up on
these anti-inflammatory therapy approaches.
Drugs Acting on Intestinal Motor and/
or Secretory Function
Traditionally this has been the preferred
therapeutic route beginning with classical
antispasmodics, laxatives of different sorts,
and antidiarrheal agents such as loperamide.
Many of these agents are currently in use by
practitioners around the world to help control
pain and diarrhea in patients with IBS.
Most antispasmodics are anticholinergic
agents that exhibit some effect, mostly
documented in vitro, reducing spasmodic
contractions of bowel muscles. They have not
been rigorously evaluated by well-designed
clinical trials. Thus, their clinical efficacy
remains in question despite over 50 years of
use for pain control and diarrhea. Peppermint
oil is an antispasmodic agent with a different
mechanism of action (reduces influx of calcium
in smooth muscle cells). Other agents sharing
this mechanism of action include otilonium
bromide and mebeverine. This latter class of
agents do not have anticholinergic side effects.
However, newer and more refined agents
have come along. Linaclotide is a molecule that
promotes intestinal secretion and appears to
inhibit visceral pain signals. It is particularly
useful for the treatment of IBS-C. However, the
higher capsule dosage of linaclotide (290 lg),
showing antinociceptive visceral effects in the
clinical trials, carries a relatively high
probability of inducing annoying diarrhea.
Likewise, lubiprostone, a marketed drug that
acts by promoting water secretion in the upper
intestine, also appears to be useful for the
treatment of IBS-C.
Rifaximin and Other Antibiotics in IBS
Nonabsorbable antibiotics represent a different
approach to modifying the microbiota for
therapeutic purposes. They have been
proposed on the basis of two main concepts:
control of small bowel bacterial overgrowth and
modification of colonic microbiota.
Broad-spectrum antibiotics have been
evaluated for the treatment of IBS largely on
the basis of presumed SIBO [21]. Rifaximin has
been favored on the basis of its
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nonabsorbability and good safety profile, as well
as empirical evidence of efficacy provided by
various trials [71, 72]. It appears that 10–14 days
of treatment with rifaximin (800–1650 mg/day)
may improve global IBS symptoms and
IBS-related bloating. The improvement persists
for several weeks. Efficacy has been better
documented for patients with IBS-D than for
other IBS subgroups. The mechanism of action
of rifaximin in patients with IBS improved by
this modality of treatment remains unclear.
Rifaximin shows strong antibiotic action
against bacterial species commonly found in
SIBO; however, as indicated earlier, the
symptomatic benefit produced by rifaximin
could also be mediated through modulation of
the colonic microbiome ecosystem. With
rifaximin therapy, hydrogen gut production
generally diminishes in association with
symptomatic improvement. Rifaximin shows
greater efficacy in relieving IBS symptoms than
previously tried broad-spectrum antibiotics,
possibly on account of the higher local
concentrations achieved by the unabsorbable
rifaximin molecule [73]. Other potential
mechanisms, albeit not fully evaluated,
include putative anti-inflammatory actions of
rifaximin and modifying effects on microbiota
function including bacterial virulence and
bacterial metabolic activity that in turn may
lead to normalization of intestinal motility and
attenuation of visceral hyperalgesia [74].
Neurogastroenterological Therapeutic
Agents
As pointed out earlier, a number of key
neurotransmitters, neural circuits, and
integrated brain, spinal, and ganglia structures
probably contribute to the generation of pain
and associated symptoms in patients with IBS.
Unfortunately we are often unable to determine
at which level or levels along the brain–gut axis
the most relevant disturbances are occurring. It
seems likely that the role of central versus
peripheral regulatory dysfunction varies
considerably among individual patients with
IBS. Generally speaking, the more severe and
refractory the pain component is, the greater
the participation of the brain is in the
pathogenesis of symptoms [41].
Neuropharmacological treatments are to some
extent hampered by uncertainty as to the
mechanisms involved. Thus, best results are
often obtained by drugs or combination of
drugs that act simultaneously upon central
and peripheral drug targets.
Psychological approaches also appear to be
effective, although highly dependent on time
and operator skills. Clinicians should be aware
of the remarkably high placebo response rates
(35–70%) observed in most controlled trials of
IBS and other functional-type conditions. In
practice, many physicians take advantage of
these positive placebo effects although
unfortunately they tend to be short lived.
Some lifestyle recommendations can probably
be included among psychological approaches.
Other more formal and structured modalities of
psychotherapy have been employed but being
time consuming and available only at
specialized centers has limited their general
use. Hypnotherapy and behavioral
modification techniques must be included in
this category.
Antidepressant drugs have a role in the
management of IBS. These agents have several
principal objectives: to attenuate visceral
hypersensitivity, to regulate gastrointestinal
motility, to improve mood and reduce
anxiety, to control anorexia, and to improve
sleep. These objectives are best prioritized by
carefully assessing first the clinical features
perceived in a given patient. This facilitates
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taking advantage of pharmacological properties
of different drugs or combination of drugs to
maximize favorable effects.
Control of abdominal pain via attenuation
of visceral hypersensitivity is a major
therapeutic objective in most patients. Modern
antidepressants with combined inhibitory
affinity for serotonin–norepinephrine reuptake
inhibitors (SNRI) such as venlafaxine and
duloxetine are generally preferred to pure
serotonin reuptake inhibitors (SRI) like
fluoxetine, paroxetine, or sertraline. Classic
tricyclic antidepressants such as amitriptyline,
nortriptyline, or desipramine can also be quite
effective for pain-relieving purposes but tend to
induce constipation (thus, they are more useful
for IBS-D). However, other less favorable eye
and prostate side effects of the older tricyclic
drugs may also limit their use.
Some antidepressants with histamine H1
receptor affinity tend to produce somnolence
and weight gain (i.e., mirtazapine). These
properties may be useful to help some patients
obtain better sleep and to stimulate their
appetite but may be inconvenient to other
patients. Side effects of some antidepressants
such as sexual dysfunction, arrhythmia,
restlessness, and orthostatic hypotension may
pose difficulties in some cases and also limit
their usefulness. Furthermore, it has been
pointed out that side effects tend to be more
common and limiting when antidepressants are
used for IBS than when used for major
depression, perhaps reflecting the peculiarities
of functional-type patients. As a rule, off-label
treatment of IBS with antidepressants involves
much lower doses than for overt psychiatric
disorders. However, some patients with IBS are
truly affected by anxiety/depression and may
benefit from standard doses of these drugs.
Agents that Modify Colonic Fluid
and Motor Dynamics
Alosetron, a serotonin 5HT3 antagonist, was
introduced in the late 1990s in the USA for the
treatment of IBS-D. Subsequently it was
withdrawn from the market after reports of
patients who developed severe constipation
and/or ischemic colitis and then reintroduced
at a lower recommended dose under a risk
management program. Ondansetron, an
antiemetic agent with a related
pharmacodynamic profile, appears to be an
effective substitute at doses as low as 2 mg
every other day. Ramosetron, another 5HT3
receptor antagonist, is showing encouraging
outcomes in recent trials [75].
Eluxadoline, recently approved in the USA
for the treatment of IBS-D, is a l-opioid receptor
agonist/d-opioid receptor antagonist/k-receptor
agonist. The three major receptors (k, d, and l)
are found in the enteric nervous system,
smooth muscle cells, and pacemaker cells of
the gastrointestinal tract. Loperamide, a
well-known antidiarrheal agent, is a l-opioid
receptor antagonist with limited capacity to
cross the blood–brain barrier. Its main drawback
in patients with IBS-D is that it tends to induce
excess constipation. Eluxadoline’s l-agonist
affect probably accounts for its antidiarrheal
action, whereas its d-opioid receptor
antagonism accounts for is modulatory effects
on visceral hypersensitivity and attenuates the
strong motility inhibitory effect of l-agonism
[76]. Thus, it does not exhibit the strong
constipating effect of loperamide.
Furthermore, the d agonist action of
eluxadoline appears to prevent the
development of tolerance. Eluxadoline may
also inhibit neurogenically mediated bowel
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secretion, further controlling diarrhea. Clinical
phase III studies have been completed on
patients with IBS-D using either 75 or 100 mg
tablets of eluxadoline twice daily for 26 weeks.
Results showed significant improvement in
stool frequency and consistency, as compared
to placebo, as well as improvement in
abdominal pain for the entire duration of the
study (26 weeks) though only for the higher
100 mg twice-daily dose. Thus, a standard
dosage of 100 mg twice daily has been
recommended for general practice. The safety
profile of eluxadoline is reasonably
acceptable with the most common adverse
effects being constipation (usually mild),
nausea and vomiting or abdominal pain. Some
concern has been raised for the rare (\1%) but
significant event of sphincter of Oddi spasm
with elevated liver enzymes and/or mild
pancreatitis. All cases with pancreatitis had
absent gallbladders and, therefore, a lower
dose of 75 mg twice daily may be more
appropriate for previously cholecystectomized
patients. Also, patients prone to use excess
alcohol should be warned of the increased risk
of pancreatitis with l-agonist agents such as
eluxadoline.
Bile Acid Sequestrants
Cholestyramine is a nondigestible resin that
binds to bile acids in the intestine and prevents
their irritating colonic effects while increasing
their excretion in feces.Cholestyraminehasbeen
widely employed in various diarrheal conditions
associated with excess colonic bile acids. It
appears to be effective in patients with IBS-D
with elevated bile acid excretion [44].
Cholestyramine is unpalatable, which decreases
patient compliance and may induce
uncomfortable symptoms on its own such as
constipation, flatulence, bloating, and others,
but these are usually minor [77]. Colestipol is a
somewhat more palatable bile acid sequestrant
with similar action. Colesevelam is the latest
sequestrant to be developed and it is available in
tablet formwhich increases its acceptability [78].
Bile acid synthesis increases during colesevelam
therapy and appears to compensate for increased
fecal bile acid loss, hence preventing fat
malabsorption in the proximal small bowel
[43]. A trial of bile acid sequestrants may be
appropriate for patients with IBS-D.
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